JEFFREY A POTTS
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- BAY CITY, MI
- NPI
- 1700804820
- Received
- $119,315 in 69 records, 2019 to 2025 ($1,045 general, $118,270 research)
- As principal investigator
- $14,675,088 of research payments to others in 281 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 18 | $329 |
| 2024 | General payment | 10 | $197 |
| 2024 | Research payment | 5 | $114,216 |
| 2023 | General payment | 15 | $239 |
| 2023 | Research payment | 1 | $535 |
| 2022 | General payment | 4 | $62 |
| 2022 | Research payment | 3 | $453 |
| 2021 | General payment | 3 | $118 |
| 2020 | General payment | 6 | $98 |
| 2020 | Research payment | 3 | $1,966 |
| 2019 | Research payment | 1 | $1,098 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 12 | $117,479 | 2019–2024 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $790 | 2020 |
| Novo Nordisk Inc | 8 | $140 | 2020–2025 |
| Lilly USA, LLC | 10 | $103 | 2022–2025 |
| GlaxoSmithKline, LLC. | 5 | $91 | 2020–2025 |
| RedHill Biopharma Inc. | 1 | $76 | 2021 |
| Novartis Pharmaceuticals Corporation | 3 | $71 | 2023–2024 |
| Astellas Pharma US Inc | 3 | $68 | 2023–2025 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 | 2025 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 | 2025 |
| PFIZER INC. | 2 | $38 | 2023–2025 |
| Amgen Inc. | 2 | $35 | 2024–2025 |
| Organon Llc | 2 | $32 | 2022–2023 |
| Axsome Therapeutics, Inc. | 1 | $25 | 2024 |
| Boston Scientific Corporation | 1 | $25 | 2024 |
| Inspire Medical Systems, Inc. | 1 | $23 | 2025 |
| Seqirus USA Inc | 1 | $22 | 2023 |
| Dexcom, Inc. | 1 | $21 | 2021 |
| Eisai Inc. | 1 | $21 | 2020 |
| Genentech USA, Inc. | 1 | $20 | 2021 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 | 2024 |
| Amarin Pharma, Inc. | 1 | $18 | 2020 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 | 2025 |
| Hologic Sales and Service, LLC | 1 | $16 | 2020 |
| ABBVIE INC. | 1 | $15 | 2022 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 | 2025 |
| Abbott Laboratories | 1 | $15 | 2025 |
| Exact Sciences Corporation | 1 | $15 | 2025 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 13 | $118,270 |
| Food and Beverage | 54 | $962 |
| Honoraria | 1 | $76 |
| Education | 1 | $6 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-02 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-11-24 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-06 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-10-28 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-10-14 | ARS Pharmaceuticals Operations, Inc. | $17 | Food and Beverage | In-kind items and services | NEFFY Drug, ALLERGY | 2025 | |
| 2025-10-14 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-10-06 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2025 | |
| 2025-09-30 | Abbott Laboratories | $15 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-09-18 | Otsuka America Pharmaceutical, Inc. | $18 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-08-21 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-08-11 | Inspire Medical Systems, Inc. | $23 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2025-07-09 | Exact Sciences Corporation | $15 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2025 | |
| 2025-05-13 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-05-06 | Astellas Pharma US Inc | $32 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2025 | |
| 2025-04-10 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-03-13 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-02-24 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-02-11 | Otsuka America Pharmaceutical, Inc. | $21 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2024-12-02 | Axsome Therapeutics, Inc. | $25 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2024 | |
| 2024-11-14 | Boston Scientific Corporation | $25 | Food and Beverage | In-kind items and services | WATCHMAN FLX Device, WATCHMAN FLX_IC | 2024 | |
| 2024-10-31 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-10-17 | Astellas Pharma US Inc | $17 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $22,510 | Research payment | Cash or cash equivalent | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | 2024 | |
| 2024-09-23 | Eli Lilly and Company | $81,783 | Research payment | Cash or cash equivalent | A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE | 2024 | |
| 2024-09-23 | Eli Lilly and Company | $5,609 | Research payment | Cash or cash equivalent | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2024 | |
| 2024-09-23 | Eli Lilly and Company | $3,427 | Research payment | Cash or cash equivalent | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERE | 2024 | |
| 2024-09-20 | Eli Lilly and Company | $886 | Research payment | In-kind items and services | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN | 2024 | |
| 2024-08-13 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-06-18 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-05-07 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-02-12 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-01-15 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-01-09 | Bayer Healthcare Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2024 | |
| 2023-12-05 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2023 | |
| 2023-11-27 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2023 | |
| 2023-09-28 | Seqirus USA Inc | $22 | Food and Beverage | In-kind items and services | Fluad Quadrivalent Biological, Vaccines | 2023 | |
| 2023-09-21 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-08-22 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | 2023 | |
| 2023-08-08 | Novartis Pharmaceuticals Corporation | $25 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-07-07 | Astellas Pharma US Inc | $19 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2023 | |
| 2023-06-22 | GlaxoSmithKline, LLC. | $30 | Food and Beverage | In-kind items and services | AREXVY Drug, RESPIRATORY | 2023 | |
| 2023-06-21 | Eli Lilly and Company | $535 | Research payment | In-kind items and services | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2023 | |
| 2023-06-15 | Organon Llc | $14 | Food and Beverage | In-kind items and services | NEXPLANON Drug, ETONOGESTREL | 2023 | |
| 2023-06-14 | Lilly USA, LLC | $5 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2023 | |
| 2023-06-14 | Lilly USA, LLC | $1 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2023 | |
| 2023-06-08 | Novartis Pharmaceuticals Corporation | $25 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-04-11 | Lilly USA, LLC | $0 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-04-10 | Lilly USA, LLC | $9 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-03-21 | Lilly USA, LLC | $6 | Education | In-kind items and services | 2023 | ||
| 2022-07-12 | Organon Llc | $18 | Food and Beverage | In-kind items and services | NEXPLANON Drug, ETONOGESTREL | 2022 | |
| 2022-06-23 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-05-27 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-04-29 | Eli Lilly and Company | $137 | Research payment | In-kind items and services | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2022 | |
| 2022-04-13 | Eli Lilly and Company | $158 | Research payment | In-kind items and services | A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMEN | 2022 | |
| 2022-04-13 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-04-05 | Eli Lilly and Company | $158 | Research payment | In-kind items and services | RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3526318 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | 2022 | |
| 2021-10-25 | RedHill Biopharma Inc. | $76 | Honoraria | In-kind items and services | 2021 | ||
| 2021-04-14 | Dexcom, Inc. | $21 | Food and Beverage | In-kind items and services | DEXCOM G6 TRANSMITTER Device, ENDOCRINOLOGY | 2021 | |
| 2021-02-08 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Erivedge Biological, BioOncology | 2021 | |
| 2020-09-10 | Hologic Sales and Service, LLC | $16 | Food and Beverage | In-kind items and services | Surepath Device, Diagnostics | 2020 | |
| 2020-08-13 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2020 | |
| 2020-07-30 | Amarin Pharma, Inc. | $18 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-07-23 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-07-21 | Eisai Inc. | $21 | Food and Beverage | Cash or cash equivalent | Dayvigo Drug, Neurology | 2020 | |
| 2020-06-25 | Eli Lilly and Company | $827 | Research payment | In-kind items and services | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF OSTEOARTHRITIS | 2020 | |
| 2020-06-25 | Eli Lilly Export S.A. Puerto Rico Branch | $790 | Research payment | In-kind items and services | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3016859 FOR THE TREATMENT OF DIABETIC PERIPHERAL NE | 2020 | |
| 2020-05-27 | Kowa Pharmaceuticals America, Inc. | $13 | Food and Beverage | Cash or cash equivalent | Livalo Drug, Cardiovascular | 2020 | |
| 2020-03-26 | Eli Lilly and Company | $348 | Research payment | In-kind items and services | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2020 | |
| 2019-11-21 | Eli Lilly and Company | $1,098 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE E | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-04 | Eli Lilly Export S.A. Puerto Rico Branch | GREAT LAKES RESEARCH GROUP INC | $550 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PART | 2025 |
| 2025-11-11 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $466 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PART | 2025 |
| 2025-07-28 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $600,463 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE | 2025 |
| 2025-07-21 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $9,475 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2025 |
| 2025-07-21 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $8,725 | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2025 |
| 2025-06-27 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $27,095 | A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO | 2025 |
| 2025-05-27 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $2,404 | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2025 |
| 2025-05-27 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $1,201 | A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO | 2025 |
| 2025-04-20 | Eli Lilly and Company | Driscoll Childrens Hospital | $3,080 | A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BIMAGRUMAB AND TIRZEPATIDE, ALONE OR IN COMBINATION, TO | 2025 |
| 2025-03-24 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $37,645 | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERE | 2025 |
| 2025-01-31 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $703 | A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE | 2025 |
| 2025-01-31 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $842 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2025 |
| 2025-01-31 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $99 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2025 |
| 2025-01-27 | Eli Lilly and Company | Driscoll Childrens Hospital | $2,704 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN | 2025 |
| 2025-01-17 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $6,160 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN | 2025 |
| 2025-01-07 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $811,986 | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | 2025 |
| 2025-01-06 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $733,734 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN | 2025 |
| 2025-01-06 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $389,885 | A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE | 2025 |
| 2025-01-06 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $774,779 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2025 |
| 2025-01-02 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $812 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2025 |
| 2024-12-02 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $33,815 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN | 2024 |
| 2024-11-12 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $326 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN | 2024 |
| 2024-10-28 | Eli Lilly and Company | Driscoll Childrens Hospital | $3,758 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN | 2024 |
| 2024-10-01 | Eli Lilly and Company | RESEARCH FOUNDATION OF STATE UNIV OF NY | $571 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN | 2024 |
| 2024-08-13 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $32 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2024 |
| 2024-07-10 | Eli Lilly and Company | Great Lakes Clinical Trials | $640 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2024 |
| 2024-07-10 | Eli Lilly and Company | Great Lakes Clinical Trials | $19 | A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE | 2024 |
| 2024-06-17 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $1,075 | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2024 |
| 2024-05-14 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $500 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2024 |
| 2024-02-13 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $1,246 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2024 |
| 2024-02-05 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $29,900 | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2024 |
| 2024-01-31 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $594 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2024 |
| 2024-01-31 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $5,186 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2024 |
| 2024-01-25 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $1,230 | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERE | 2024 |
| 2024-01-11 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $5,062 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2024 |
| 2024-01-11 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $2,785 | A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE | 2024 |
| 2024-01-02 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $1,187,816 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2024 |
| 2024-01-02 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $1,317,236 | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | 2024 |
| 2024-01-02 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $75,537 | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERE | 2024 |
| 2024-01-02 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $877,951 | A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE | 2024 |
| 2023-12-22 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $3,675 | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE | 2023 |
| 2023-10-25 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $1,697 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-10-20 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $3,068 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF N | 2023 |
| 2023-10-16 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $275,011 | A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE | 2023 |
| 2023-10-06 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $5,500 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF N | 2023 |
| 2023-10-03 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $2,073 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-10-03 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $500 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-09-01 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $827,834 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2023 |
| 2023-09-01 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $272,612 | A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | 2023 |
| 2023-09-01 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $11,788 | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION T | 2023 |
| 2023-08-18 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $369 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-08-10 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $365 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-08-10 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $589 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-07-06 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $2,756 | A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE | 2023 |
| 2023-06-26 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $2,316 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2023 |
| 2023-06-09 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $15,000 | A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE | 2023 |
| 2023-06-08 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $6,407 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETE | 2023 |
| 2023-06-06 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $20,205 | A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT | 2023 |
| 2023-05-25 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $4,049 | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERE | 2023 |
| 2023-05-24 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $33 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-05-19 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $500 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-04-25 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $202 | A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2023 |
| 2023-04-25 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $187 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATM | 2023 |
| 2023-03-30 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $2,195 | A PHASE 3 12 MONTH OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2023 |
| 2023-03-28 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $667 | A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT | 2023 |
| 2023-03-27 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $20,141 | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY383247 | 2023 |
| 2023-03-27 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $5,341 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATM | 2023 |
| 2023-03-02 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $500 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-02-22 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $1,377 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-02-14 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $277,328 | RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3857210 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | 2023 |
| 2023-02-14 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $255,687 | A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT | 2023 |
| 2023-02-13 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $144,948 | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERE | 2023 |
| 2023-02-02 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $2,565 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-01-31 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $594 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATM | 2023 |
| 2023-01-30 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $120,120 | A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT | 2023 |
| 2023-01-30 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $3,303 | A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT | 2023 |
| 2023-01-26 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $2,818 | RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3857210 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | 2023 |
| 2023-01-26 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $3,272 | A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT | 2023 |
| 2023-01-20 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $2,345 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-01-20 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $1,908 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-01-20 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $1,874 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-01-20 | Averitas Pharma Inc. | GREAT LAKES RESEARCH GROUP INC | $2,282 | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFI | 2023 |
| 2023-01-18 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $158 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF N | 2023 |
| 2023-01-17 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $290 | RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2023 |
| 2023-01-10 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $4,494 | A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERE | 2023 |
| 2023-01-09 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $681,960 | RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2023 |
| 2023-01-06 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $15,000 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF N | 2023 |
| 2023-01-03 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $3,812 | RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | 2023 |
| 2022-12-29 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $15,642 | A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants With Moderately-to-Seve | 2022 |
| 2022-12-28 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $12,270 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF N | 2022 |
| 2022-12-16 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $2,500 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF N | 2022 |
| 2022-12-06 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $3,340 | MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT | 2022 |
| 2022-11-21 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $13,000 | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2022 |
| 2022-11-21 | Eli Lilly and Company | GREAT LAKES RESEARCH GROUP INC | $13,000 | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2022 |
| 2022-11-17 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $3,671 | RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3857210 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN | 2022 |
| 2022-11-17 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $3,815 | A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMEN | 2022 |
| 2022-11-17 | Eli Lilly and Company | GREAT LAKES MEDICAL RESEARCH LLC | $2,415 | A MASTER PROTOCOL FOR RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMEN | 2022 |
| 2022-11-08 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $12,270 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF N | 2022 |
| 2022-11-08 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $825 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF N | 2022 |
| 2022-11-08 | PFIZER INC. | GREAT LAKES RESEARCH GROUP INC | $821 | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF N | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bay City, MI, county Bay County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Bay City, MI | County Bay County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 32,320 | 103,008 | 10,077,761 |
| Population, 2020 census P1 | 32,661 | 103,856 | 10,077,331 |
| Median age B01002 | 40.7 | 43.9 | 40.2 |
| Under 18 B01001 | 20.2% | 19.6% | 21.2% |
| 65 and over B01001 | 17.7% | 21.9% | 18.6% |
| Households B11001 | 14,677 | 45,103 | 4,076,369 |
| Foreign born B05002 | 2.3% | 1.3% | 7.2% |
| Median household income B19013 | $49,420 | $61,763 | $72,875 |
| Median family income B19113 | $64,016 | $81,863 | $93,357 |
| Per capita income B19301 | $29,853 | $35,602 | $40,735 |
| Poverty rate B17001 | 19.1% | 13.2% | 13.2% |
| Unemployment rate B23025 | 6.7% | 4.3% | 5.7% |
| Civilian labor force B23025 | 15,738 | 50,658 | 5,018,449 |
| Mean commute (minutes) B08013 | 21.3 | 23.1 | 24.2 |
| Bachelor's degree or higher B15003 | 18.8% | 22.1% | 32.4% |
| Housing units B25001 | 16,078 | 48,659 | 4,622,236 |
| Owner-occupied B25003 | 70.1% | 77.0% | 73.2% |
| Renters B25003 | 29.9% | 23.0% | 26.8% |
| Median home value B25077 | $97,600 | $152,200 | $231,600 |
| Median gross rent B25064 | $766 | $860 | $1,129 |
| White, not Hispanic B03002 | 80.1% | 88.2% | 72.4% |
| Black B03002 | 1.6% | 1.0% | 13.1% |
| Hispanic or Latino B03002 | 11.5% | 5.9% | 5.9% |
| Asian B03002 | 0.8% | 0.5% | 3.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bay City, MI.
Comments